The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2024 | ProvIDHe: baseline characteristics and molecular testing of pts with IDH1-mutated cholangiocarcinoma
Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, comments on the ProvIDHe study (NCT05876754), a Phase IIIb trial evaluating ivosidenib in patients with IDH1-mutant cholangiocarcinoma, previously treated with systemic therapies. The study aims to collect more safety data and evaluate efficacy in clinical practice, with a focus on patient-reported outcomes, quality of life, and medical resource utilization. This interview took place at the ESMO Asia Congress 2024, held in Singapore, Republic of Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
